IPO registrations (S-1, F-1) · Registrants
Eledon Pharmaceuticals, Inc.
- SEC CIK
- 1404281 · filings on EDGAR ↗
- Name on the registration
- Novus Therapeutics, Inc.
- Former names
- Novus Therapeutics, Inc. (2017–2020); Tokai Pharmaceuticals Inc (2007–2017)
- Registration
- Form S-1, first filed 2014-08-11, last 2020-03-25; 4 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2014-09-18; declared effective 2014-09-16; withdrawal requested 2018-09-07
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 19800 MACARTHUR BLVD., SUITE 250, Irvine, CA 92612
- Ticker
- ELDN (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Eledon Pharmaceuticals, Inc. on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2014-09-02)
- Final price
- $15.00 per share, within the range (424B4 filed 2014-09-18, an initial public offering)
- Shares sold
- 6,480,000
- Gross proceeds
- $97,200,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol TKAI
- Lead underwriters
- BMO Capital Markets; Stifel; William Blair
- Syndicate
- Janney Montgomery Scott; December 31, June 30 (2,014); Pro Forma June 30 (2,014)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Eledon Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- SEC filer: Eledon Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Person page: David A Kessler Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 17
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-08-11 | S-1 | S-1 (registration) | Tokai Pharmaceuticals Inc | 0001193125-14-305049 ↗ |
| 2014-09-02 | S-1/A | S-1/A (amendment) | Tokai Pharmaceuticals Inc | 0001193125-14-329019 ↗ |
| 2014-09-16 | S-1MEF | S-1MEF (added securities) | Tokai Pharmaceuticals Inc | 0001193125-14-343474 ↗ |
| 2014-09-16 | EFFECT | EFFECT (declared effective) | Tokai Pharmaceuticals Inc | 9999999995-14-002785 ↗ |
| 2014-09-18 | 424B4 | 424B4 (final prospectus) | Tokai Pharmaceuticals Inc | 0001193125-14-344755 ↗ |
| 2015-10-23 | EFFECT | EFFECT (declared effective) | Tokai Pharmaceuticals Inc | 9999999995-15-002861 ↗ |
| 2017-08-09 | EFFECT | EFFECT (declared effective) | Novus Therapeutics, Inc. | 9999999995-17-002069 ↗ |
| 2018-07-31 | EFFECT | EFFECT (declared effective) | Novus Therapeutics, Inc. | 9999999995-18-001961 ↗ |
| 2018-08-01 | S-1 | S-1 (registration) | Novus Therapeutics, Inc. | 0001193125-18-233511 ↗ |
| 2018-09-04 | S-1/A | S-1/A (amendment) | Novus Therapeutics, Inc. | 0001193125-18-266270 ↗ |
| 2018-09-07 | RW | RW (withdrawal request) | Novus Therapeutics, Inc. | 0001193125-18-268697 ↗ |
| 2019-06-07 | S-1 | S-1 (registration) | Novus Therapeutics, Inc. | 0001193125-19-168171 ↗ |
| 2019-06-17 | EFFECT | EFFECT (declared effective) | Novus Therapeutics, Inc. | 9999999995-19-001363 ↗ |
| 2020-03-25 | S-1 | S-1 (registration) | Novus Therapeutics, Inc. | 0001193125-20-085060 ↗ |
| 2020-04-03 | EFFECT | EFFECT (declared effective) | Novus Therapeutics, Inc. | 9999999995-20-000680 ↗ |
| 2020-12-22 | EFFECT | EFFECT (declared effective) | Novus Therapeutics, Inc. | 9999999995-20-003635 ↗ |
| 2021-05-21 | EFFECT | EFFECT (declared effective) | Eledon Pharmaceuticals, Inc. | 9999999995-21-002058 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-09-02 | S-1/A | registration statement | $13.00–$15.00 | 5,400,000 | - | Nasdaq TKAI | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2014-09-18 | 424B4 | final prospectus | $15.00 | 6,480,000 | $97,200,000 | Nasdaq TKAI | 6 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Apple Tree Partners II - Annex, L.P. | Director,TenPercentOwner; TenPercentOwner | 2 | 2014 | ||
| APPLE TREE PARTNERS II LP | Director,TenPercentOwner; TenPercentOwner | 2 | 2014 | ||
| BARBERICH TIMOTHY J | Director | 4 | 2014–2016 | ||
| Ferrante Karen Jean | Officer | Head Res. & Dev. & Chief Med. | 2 | 2014–2015 | |
| Harrison Seth Loring | Director,TenPercentOwner | 4 | 2014–2016 | ||
| Kalowski Lee | Officer | Chief Financial Officer | 7 | 2014–2015 | |
| Kessler David A. | Director | 3 | 2014–2016 | person page Fuzzy | |
| McBride John S. | Director; Officer | Chief Operating Officer | 14 | 2014–2026 | |
| Morrison Jodie Pope | Director; Director,Officer | President and CEO | 9 | 2014–2017 | |
| NOVARTIS AG | TenPercentOwner | 8 | 2014–2015 | ||
| Novartis Bioventures Ltd | TenPercentOwner | 8 | 2014–2015 | ||
| Platt Jon B. | TenPercentOwner | 1 | 2014 | ||
| QBF No. 1 Pty Ltd as trustee for Queensland BioCapital Fund No. 1 | TenPercentOwner | 1 | 2014 | ||
| QBF No. 2 Pty Ltd as trustee for Queensland BioCapital Fund No. 2 | TenPercentOwner | 1 | 2014 | ||
| Satter Muneer A | TenPercentOwner | 2 | 2014 | ||
| Stewart Susan B. | TenPercentOwner | 1 | 2014 | ||
| Thomas Robert Bain | TenPercentOwner | 1 | 2014 | ||
| Wade Denis Newell | TenPercentOwner | 1 | 2014 | ||
| Warman Investments Pty. Ltd. | TenPercentOwner | 1 | 2014 | ||
| Williams Martin D | TenPercentOwner | 1 | 2014 | ||
| Yanchik Joseph A., III | Director | 3 | 2014–2016 | ||
| Apple Tree Partners IV, L.P. | Director,TenPercentOwner | 1 | 2014 | ||
| Buckley Stephen Jr. | Director | 6 | 2015–2016 | ||
| Cohen Cheryl | Director | 6 | 2015–2019 | ||
| Quirk Gerald E | Officer | General Counsel, Executive VP | 3 | 2015 | |
| Chimovits Erez | Director; Director,TenPercentOwner | 4 | 2017–2020 | ||
| FLESHER GREGORY J. | Director,Officer | Chief Executive Officer | 8 | 2017–2020 | |
| Katkin Keith | Director | 10 | 2017–2026 | ||
| LYONS GARY A | Director | 8 | 2017–2023 | ||
| OCAMPO CHRISTINE | Officer | See Remarks | 3 | 2017 | |
| OrbiMed Israel BioFund GP Limited Partnership | Director,TenPercentOwner; TenPercentOwner | 5 | 2017–2020 | ||
| OrbiMed Israel GP Ltd. | Director,TenPercentOwner; TenPercentOwner | 5 | 2017–2020 | ||
| TURKEL CATHERINE C. | Officer | Chief Development Officer; President | 11 | 2017–2020 | |
| Kuwahara Jon | Officer | See Remarks | 8 | 2017–2020 | |
| LIFESCI INDEX PARTNERS LLC | TenPercentOwner | 2 | 2018–2019 | ||
| YOOK PAUL | TenPercentOwner | 2 | 2018–2019 | ||
| Gros David-Alexandre C | Director,Officer | Chief Executive Officer | 12 | 2020–2026 | |
| Ogier Walter C | Director | 4 | 2020–2023 | ||
| Perrin Steven | Director,Officer | President; See Remarks | 9 | 2020–2026 | |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 6 | 2020–2024 | ||
| BIOTECHNOLOGY VALUE FUND L P | Other | 6 | 2020–2024 | ||
| Biotechnology Value Trading Fund OS LP | Other | 6 | 2020–2024 | ||
| BVF GP HOLDINGS LLC | Other; TenPercentOwner | 6 | 2020–2024 | ||
| BVF I GP LLC | Other | 6 | 2020–2024 | ||
| BVF II GP LLC | Other | 6 | 2020–2024 | ||
| BVF INC/IL | Other; TenPercentOwner | 6 | 2020–2024 | ||
| BVF PARTNERS L P/IL | Other; TenPercentOwner | 6 | 2020–2024 | ||
| BVF Partners OS Ltd. | Other | 6 | 2020–2024 | ||
| LAMPERT MARK N | Other; TenPercentOwner | 6 | 2020–2024 | ||
| Logos Global Management LP | TenPercentOwner | 2 | 2020 | ||
| Lee June | Director | 6 | 2020–2026 | ||
| Little Paul Sean | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 8 | 2021–2025 | |
| Smith Bryan E. | Officer | General Counsel, Corporate Sec; See Remarks | 8 | 2021–2025 | |
| Hillson Jan | Director | 6 | 2021–2026 | ||
| Kirk Allan | Director | 4 | 2023–2026 | ||
| Robinson James A. Jr. | Director | 4 | 2023–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-05-23 | Eledon Pharmaceuticals, Inc. | Biotechnology | Indefinite | $49,999,010 | 24 | 1 |
| 2023-05-22 | Eledon Pharmaceuticals, Inc. | Biotechnology | Indefinite | $35,000,000 | 38 | 1 |
| 2020-09-25 | Novus Therapeutics, Inc. | Biotechnology | $108,144,151 | $108,144,151 | 35 | 1 |
| 2020-01-27 | Novus Therapeutics, Inc. | Pharmaceuticals | $5,828,999 | $862,278 | 10 | 1 |
| 2019-05-10 | Novus Therapeutics, Inc. | Pharmaceuticals | $28,455,174 | $862,278 | 10 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | ELEDON PHARMACEUTICALS INC. | CA | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Eledon Pharmaceuticals, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Eledon Pharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Eledon Pharmaceuticals, Inc. | CA | Trademarks (USPTO) | name and state |
| Person page | David A Kessler | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- RIGEL PHARMACEUTICALS INC CA
- Diadexus, Inc. CA
- CymaBay Therapeutics, Inc. CA
- CRESCENDO PHARMACEUTICALS CORP CA
- SPIROS DEVELOPMENT CORP II INC CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health